# reload+after+2024-01-23 14:43:12.034804
address1§315 Sigma Drive
city§Summerville
state§SC
zip§29486
country§United States
phone§843 900 3223
website§https://www.zentaris.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Klaus  Paulini Ph.D.', 'title': 'President, CEO & Executive Director', 'fiscalYear': 2022, 'totalPay': 365175, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Giuliano  La Fratta', 'title': 'Senior VP of Finance & CFO', 'fiscalYear': 2022, 'totalPay': 266120, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael  Teifel Ph.D.', 'title': 'Senior VP of Non-Clinical Development & Chief Scientific Officer', 'fiscalYear': 2022, 'totalPay': 176868, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nicola  Ammer M.D.', 'title': 'Chief Medical Officer & Senior VP of Clinical Development', 'fiscalYear': 2022, 'totalPay': 197034, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Matthias  Gerlach', 'title': 'Senior Vice President Manufacturing & Supply Chain', 'fiscalYear': 2022, 'totalPay': 224686, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.1
priceToSalesTrailing12Months§1.3669645
currency§USD
dateShortInterest§1702598400
forwardEps§-3.37
exchange§NCM
quoteType§EQUITY
shortName§Aeterna Zentaris Inc.
longName§Aeterna Zentaris Inc.
firstTradeDateEpochUtc§957965400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§47c94313-9c0e-3607-a229-7dc731cab956
gmtOffSetMilliseconds§-18000000
targetHighPrice§15.0
targetLowPrice§15.0
targetMeanPrice§15.0
targetMedianPrice§15.0
recommendationKey§none
numberOfAnalystOpinions§1
quickRatio§9.323
grossMargins§0.96823
ebitdaMargins§-2.28811
trailingPegRatio§None
